Project Grant R03OD039976

Award Date 6/10/25
Completion Date 5/31/26
Dollars Obligated $1
Federal Grant Program
93.121
Assistance Type
Project Grant
Place of Performance
Stanford, CA 94305, USA
Similar Awards
This Project Grant award from the National Human Genome Research Institute (CFDA 93.172 - Human Genome Research) provides $716,587 to Boston Children's Hospital to advance equity in rare disease genomic research. The key objectives are to: Develop and implement a Diversity, Equity, and Inclusion toolkit within the Broad Institute's Rare Genomes Project to improve engagement and participation from historically underrepresented populations in rare disease genomic studies. This will involve...
This $993,446 Project Grant award from the National Human Genome Research Institute (CFDA 93.172 - Human Genome Research) will support the development of statistical and machine learning approaches to decode the regulatory activity underlying disease variants, link variants to genes in relevant cell types, and identify disease-critical co-operative programs of genes and genomic elements. The key objectives are to: 1) leverage single-cell multi-omics data to improve strategies for linking...
This $409,896 Project Grant awarded by the National Institute of General Medical Sciences (NIGMS) under the Biomedical Research and Research Training program (CFDA 93.859) supports the development of novel statistical methods and analyses to leverage functional genomics data, in conjunction with genome-wide association study (GWAS) data, to identify and characterize the functional effects of genetic variants and their roles in diseases. The key objectives are: (1) to establish a powerful...
This Project Grant award from the National Human Genome Research Institute (NHGRI), under the Human Genome Research federal grant program (CFDA 93.172), provides $757,157 to the University of California, San Diego (UC San Diego) to develop complementary experimental and computational strategies for high-throughput characterization of the impact of genetic variants. The key objectives are to: 1) Develop a method called SCBE-SEQ that combines genome editing with single-cell sequencing to...
This Project Grant award, valued at $491,366, was issued by the National Human Genome Research Institute (NHGRI) under the Human Genome Research federal grant program (CFDA 93.172). The award is focused on developing new algorithms to robustly map disease-associated genetic variants to critical target genes, particularly in underrepresented populations. Key objectives include: Improving the ability to identify disease-critical genes in non-European populations where data is limited. Developing...
This federal Project Grant award from the National Human Genome Research Institute (CFDA 93.172 - Human Genome Research) totaling $1,435,298 will fund a project titled "HIGH THROUGHPUT FUNCTIONAL ANNOTATION OF THE IMPACT OF HUMAN UTR SEQUENCE VARIATION ON GENE FUNCTION AND PROTEIN OUTPUT" at Yale University from February 1, 2025 to January 31, 2029. The goal of this project is to develop new genomic and computational approaches to understand the functional impact of genetic variation...
This $1,038,898.88 Project Grant award from the National Human Genome Research Institute (CFDA 93.172 - Human Genome Research) aims to develop novel approaches for integrating single-cell data with genome-wide association studies (GWAS) to elucidate the genetic architecture of complex diseases. The key objectives are to: 1) leverage single-cell epigenetic data to identify heritable disease components; 2) use single-cell data to fine-map disease variants and their mechanisms; and 3) define the...
This Project Grant award from the National Human Genome Research Institute (NHGRI), under the Human Genome Research program (CFDA 93.172), aims to develop new methods to predict disease risk among individuals with rare monogenic risk alleles. The $1,100,866 award will fund research at the Icahn School of Medicine at Mount Sinai to leverage deep learning techniques on Electronic Health Records, metabolomics, and proteomics data from sources like the UK Biobank and NIH All of Us program. The...
This federal Project Grant award from the National Institute of Dental and Craniofacial Research (NIDCR), under the Oral Diseases and Disorders Research program (CFDA 93.121), provides $1 to support the development of a cell-type specific atlas of transcription factor-element connectivity across human tissues. The project aims to integrate single-cell and single-nucleus ATAC-seq data from the GTEx and HuBMAP Common Fund projects, and apply deep learning methods to predict transcription factor...
This federal Project Grant award from the National Human Genome Research Institute (NHGRI) under the Human Genome Research (CFDA 93.172) program provides $666,831 to Stanford University to develop new techniques for using rare protein-coding variants, including loss-of-function mutations, deletions, and duplications, in burden tests to estimate the magnitude and direction of effect of each gene on a phenotype of interest. The goal is to improve the accuracy of these tests, which are often...

INTEGRATING 4DN DATA TO IDENTIFY FUNCTIONAL RARE VARIANTS IN UDN AND GTEX - ABSTRACT RARE VARIANTS ARE ABUNDANT IN THE HUMAN POPULATION AND CONTRIBUTE TO A VARIETY OF GENETIC DISEASES. HOWEVER, IDENTIFYING IMPACTFUL RARE GENETIC VARIANTS FROM THE MULTITUDE OF INCONSEQUENTIAL VARIANTS REMAINS A CHALLENGE. TRANSCRIPTOMICS HAS EMERGED AS A COMPLEMENTARY ASSAY TO IDENTIFY THE EFFECTS OF RARE NON-CODING GENETIC VARIANTS AS APPROACHES USING GENE EXPRESSION OUTLIERS HAVE ASSISTED PRIORITIZATION OF RARE VARIANTS INVOLVED IN RARE DISEASES. WE HAVE PREVIOUSLY DEVELOPED A MACHINE LEARNING MODEL, WATERSHED, TO PRIORITIZE CANDIDATE CAUSAL RARE VARIANTS BY INTEGRATING OUTLIER GENE EXPRESSION LEVELS WITH RELEVANT GENOMIC ANNOTATIONS SUCH AS CONSERVATION AND REGULATORY ELEMENT ANNOTATIONS. THIS APPROACH EXPANDS ON VARIANT EFFECT PREDICTION TOOLS THAT ARE GENOME-ONLY BY FURTHER CONSIDERING AN INDIVIDUAL'S TRANSCRIPTOME ALONGSIDE THEIR GENOME IN THE VARIANT PRIORITIZATION STRATEGY. WHILE PREVIOUS APPROACHES HAVE FOCUSED ON RARE VARIANT IDENTIFICATION IN REGIONS PROXIMAL TO THE EXPRESSION OUTLIER GENE, TYPICALLY WITHIN 10KB, GENE EXPRESSION CAN BE REGULATED IN PART BY 3D GENOMIC CONFORMATION. GIVEN INCREASING EVIDENCE THAT RARE VARIANTS IMPACT DNA ARCHITECTURE AND 3D NUCLEAR ORGANIZATION CAN INFLUENCE THE PATHOGENESIS OF RARE DISEASE, WE HYPOTHESIZE INTEGRATING GENOME TOPOLOGY WILL ENABLE THE IDENTIFICATION OF RARE VARIANTS WITH FUNCTIONAL ACTIVITY THAT ARE MORE DISTAL TO THE EXPRESSION OUTLIER GENE. OUR STUDY AIMS TO LEVERAGE COMMON FUND DATASETS TO EXTEND WATERSHED BY UTILIZING 3D NUCLEOME INFORMATION FROM THE 4D NUCLEOME (4DN) PROGRAM TO PRIORITIZE CAUSAL RARE VARIANTS IN TRANSCRIPTOME DATA FROM THE UNDIAGNOSED DISEASE NETWORK (UDN) AND THE GENOTYPE-TISSUE EXPRESSION (GTEX) PROJECT. OUR PROPOSED PROJECT WILL INTEGRATE CELL-TYPE SPECIFIC AND EXPRESSION-MATCHED ANNOTATIONS FROM DILUTION HI-C EXPERIMENTS IN 4DN WITH RNA-SEQ DATA FROM GTEX AND UDN. WE WILL ASSESS RARE VARIANT ENRICHMENT IN HIGHLY- CONNECTED LOCI NEAR GENE EXPRESSION OUTLIERS AND DEVELOP WATERSHED-3D TO UTILIZE 4DN ANNOTATIONS TO PRIORITIZE IMPACTFUL RARE VARIANTS IN HEALTHY INDIVIDUALS AND THOSE WITH RARE DISEASES. WE WILL EVALUATE ITS PERFORMANCE USING N2 PAIRS, AN APPROACH WE HAVE PREVIOUSLY APPLIED TO BOTH GTEX AND UDN, WHERE TWO OR MORE INDIVIDUALS SHARE THE SAME RARE VARIANT AND THE PREDICTED OUTLIER SCORE FOR ONE INDIVIDUAL MAY BE EVALUATED BASED ON THE OBSERVED OUTLIER STATUS OF THE OTHER INDIVIDUAL(S) SHARING THE VARIANT. OUR OUTCOME WILL BE WHETHER 3D ANNOTATIONS IMPROVE RARE VARIANT DETECTION COMPARED WITH PREVIOUS MODELS THAT DO NOT INCLUDE GENOME TOPOLOGY ANNOTATIONS AND PRIORITIZE IMPACTFUL, LONG-RANGE RARE REGULATORY VARIANTS IN UDN SAMPLES. WE WILL PROVIDE THE GENOMICS COMMUNITY WITH ANNOTATIONS FOR RARE VARIANTS IN GTEX AND UDN AND AN EXPANDED WATERSHED-3D MODEL IN A REPRODUCIBLE, CLOUD-READY WORKFLOW. COMBINED, THIS PROPOSAL REPRESENTS A SIGNIFICANT OPPORTUNITY TO INTEGRATE OUR EMERGING UNDERSTANDING OF NUCLEAR TOPOLOGY AND ORGANIZATION WITH GENETIC INFORMATION TO MORE SYSTEMATICALLY PRIORITIZE FUNCTIONAL RARE VARIANT EFFECTS AND THEIR ROLES IN HEALTH AND DISEASE.

Posted 6/10/25, 12:00 AM